QS-21 Flexibility of Formulation By Keith Cohn Posted 28 September, 2015 In QS-21 Flexibility of Formulation2015-09-282022-04-14https://desertking.com/wp-content/uploads/2023/04/dk-color.pngDesert Kinghttps://desertking.com/wp-content/uploads/2015/09/Pharma-2.jpg200px200px 0 Recent PostsOboge, H., et al. Immunogenicity of Theileria parva p67C Antigen Delivered via Adjuvanted CoPoP Liposomes in Cattle and Mice. Vaccines (Basel). 2026 May 20, 14(5):459. PMID: 42188829Márquez, P.G., et al. Cooperative supramolecular integration of QS-21 into polymeric micelles as a tunable nanoadjuvant platform for subunit vaccines. RSC Adv. 2026 May 1, 16(25):22897-22915. PMID: 42080164Lützelschwab, C., et al. Evaluation of a novel experimental NanoQuil vaccine against Staphylococcus aureus-induced mastitis. J Dairy Res. 2026 May 22:1-8. PMID: 42170826Liang, R., et al. Ganglioside GM3 and Lipid A Mimetic Conjugate Combined with EcMPLA and QS-21 as a Potential Vaccine Candidate for Cutaneous Melanoma Immunotherapy. J Med Chem, 2026 May 14, 69(9):11434-11447. PMID: 42077094
